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Purpose: The dietary supplement Mirtogenol® was previously shown to lower elevated intraocu-
lar pressure (IOP). We here present the effects of this supplement on IOP in comparison as well 
as in combination with latanoprost eye drops.
Methods: Seventy-nine patients with asymptomatic ocular hypertension were randomly 
assigned to three groups receiving either the supplement, or latanoprost eye drops, or both in 
combination. Intraocular pressure and retinal blood flow were investigated in monthly intervals 
over 24 weeks.
Results: Mirtogenol alone lowered IOP from baseline 38.1 to 29.0 mmHg after 16 weeks, with 
little further improvement during the following eight weeks. Latanoprost rapidly lowered IOP 
from baseline 37.7 to 27.2 mmHg within four weeks, without further effects thereafter. The 
combination of the supplement and latanoprost lowered IOP from 38.0 to 27.3 mmHg after 
four weeks, and further decreased IOP to 24.2 mmHg after six weeks. After 24 weeks IOP with 
the combination treatment (23.0 mmHg) was significantly lower than with latanoprost alone 
(27.2 mmHg). Mirtogenol and latanoprost individually showed comparable effects for   gradually 
increasing central artery blood flow with treatment duration. Combination   treatment showed 
higher systolic blood flow velocity throughout the trial period. The diastolic blood flow velocity 
gradually increased with treatment duration in all three groups. From twelve weeks onwards, the 
diastolic component with   combination treatment was higher than with individual treatments.
Conclusions: Mirtogenol lowered elevated IOP in patients almost as effectively as latanoprost, 
however, it takes much longer (24 vs 4 weeks). The combination of both was more effective 
for lowering IOP and the combination yielded better retinal blood flow. No serious side effects 
occurred during the study, apart from standard side effects in patients related to Latanoprost. 
These promising results warrant further research of Mirtogenol with a larger patient group.
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Introduction
Dietary supplementation with Mirtogenol®: a combination of two phenolic extracts 
from bilberry (Mirtoselect®) (standardized to 36% anthocyanins; USP 31) and French 
maritime pine bark (Pycnogenol®) (standardized to 70% procyanidins; USP 31), has 
previously been demonstrated to improve intraocular pressure (IOP) in   asymptomatic 
patients.1 In this previous open, controlled, exploratory pilot trial a significant 
  improvement of ocular blood flow was found after three-month intake of Mirtogenol. 
The lowered IOP coincided with a significant ocular blood flow improvement of 
patients and thus the effect on IOP was attributed to this effect. Both Mirtoselect and 
Pycnogenol have previously been extensively researched in ophthalmology for treat- Clinical Ophthalmology  2010: 4 submit your manuscript | www.dovepress.com
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ment of diabetic retinopathy.2–4 These studies pointed to a con-
trol of capillary leakage and decreased retinal bleedings.
Endothelial dysfunction and vascular structural changes 
are considered as major contributing factors to altered 
  hemodynamics, elevated IOP, and, eventually, open-angle 
glaucoma.5 Pycnogenol was shown in human pharmacologic 
studies to improve endothelial function.6 Mirtoselect was 
shown to counteract hyperpermeability of ciliary capillaries, 
initiated by paracentesis, as measured by the Evans Blue 
concentration in the aqueous humor.7 The initial study on 
Mirtogenol suggested a significantly increased ocular blood 
flow and this effect was suggested to be predominantly 
responsible for the decreased IOP.1
The rationale for the study presented here was to find 
out how the intake of the dietary supplement affects IOP in 
patients taking standard eye drop treatment with   latanoprost. 
Since prostaglandin F2α analogs decrease IOP by   increasing 
the drainage of aqueous humor, while Mirtogenol is assumed 
to act on humor secretion, the possibility exists of an additive 
and/or synergistic interaction between these two principles. In 
this study we investigated IOP and ocular hemodynamics in 
asymptomatic patients presenting with ocular   hypertension. 
They were assigned to three groups for receiving either 
latanoprost, Mirtogenol, or both, over an investigational 
period covering 24 weeks.
Methods
Participants for this study were recruited from patients with 
ocular hypertension diagnosed by ophthalmologists who were 
sent for a general cardiovascular check-up to the University 
Hospital of Chieti-Pescara.
Subjects presenting with any cardiovascular diseases 
requiring medical treatment, and those who had had surgery, 
radiotherapy or chemotherapy in the last three months were 
excluded. None of the patients was hypertensive. Subjects 
who were pregnant, breastfeeding, or planning conception 
were excluded as well.
Seventy-nine subjects presenting with diagnosed 
  intraocular hypertension ($35 and #40 mmHg) were 
recruited for this investigation. All subjects had complete eye 
exams, showing no signs of primary open-angle glaucoma. 
Their cup-to-disk ratio was lower than 0.5, they had a central 
corneal thickness greater than 555 µm, and no visual field 
defects. Subjects with any degenerative eye disorder were 
excluded. The general cardiovascular examination ensured 
that patients had no systemic diseases.
All subjects were informed about the aim of the investiga-
tion and treatment procedure, according to the Declaration 
of Helsinki, and gave their written informed consent for 
participation in this investigation.
Patients were randomly divided into three groups to 
receive latanoprost, Mirtogenol, or both   simultaneously, as 
detailed in Table 1. Patients in this study had   ocular hyperten-
sion in absence of symptoms. The dietary   supplement was 
previously demonstrated to significantly lower elevated IOP. 
Nonetheless, it was considered a   necessity that a patient’s 
IOP should improve substantially in response to treatment 
with the dietary supplement within a given time period of 
two months. In any case where their IOP did not respond, 
they were to be given latanoprost in addition. Under these 
conditions the ethical committee of the University of Chieti 
Pescara approved the study.
Mirtogenol was taken as one tablet in the morning. The 
tablet contained, as active ingredient, 80 mg Mirtoselect® 
  standardized bilberry extract (Indena, Milan, Italy).8 This 
  Vaccinium myrtillus L extract is composed of flavonoids, and 
standardized to contain 36% anthocyanins, with conformance 
to the USP 31 on ‘Powdered Bilberry Extract’. Mirtogenol 
  tablets further contain 40 mg French maritime pine bark extract, 
Pycnogenol (Horphag Research, London, UK),9 which consists 
of flavan-3-ols standardized to 70% ± 5% procyanidins with 
conformance to the USP 31 on “Maritime Pine Extract”.6,7 
Xalatan® (Pharmacia, Pfizer) was taken one drop per eye daily, 
equivalent to 1.5 µg latanoprost, in the evening.
The intraocular pressure was always measured in the 
morning between 9 and 10 a.m. The patient was seated before 
a slit lamp and Goldmann’s contact applanation tonometer 
was used. The IOP measurements of a given patient were 
always performed by the same person to rule out variations 
from one investigator to another. No drugs were used within 
two hours before measurements. The patient had been   resting, 
sitting for at least 20 minutes, avoiding ‘rush’   measurements 
made as soon as the patients arrived into the clinic. The 
patients had been briefed with the procedures and were 
familiar with the measurement   environment. At each visit the 
IOP was measured in triplicate, with 10-minute intermissions 
between measurements, and mean values were recorded.
High resolution color Doppler imaging (Esaote, Genoa, 
Italy) was used to measure the peak systolic flow velocity, 
Table 1 Details of patients in the three investigational groups
Treatment group Patients: 
male + female
Age
Mirtogenol only 12 + 11 48.6 ± 3.2 years
Latanoprost only 16 + 13 49.0 ± 5.5 years
Mirtogenol and latanoprost 12 + 15 48.7 ± 4.0 yearsClinical Ophthalmology  2010: 4 submit your manuscript | www.dovepress.com
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and the end diastolic flow velocity of the central retinal artery, 
as previously described.10
Data are presented as mean values with standard 
  deviation. Since the distribution of the IOP and the central 
retinal artery blood flow were not normally distributed, and 
no standard data was available for these patients, a group of 
at least 15 subjects in each group was considered a minimal 
requirement. One-way analysis of the variance (ANOVA) for 
repeated measurements followed by post hoc Bonferroni tests 
was used for the intragroup comparisons. A value of P , 0.05 
was used as the criterion for statistical significance.
Results
The three groups of subjects were comparable for age:details 
are presented in Table I. The baseline IOP values were 
comparable with 37.7 ± 2.0 mmHg in the latanoprost 
group, 38.1 ± 2.0 mmHg in the Mirtogenol group and 
38.0 ± 3.1 mmHg in the group receiving both treatments. 
None of the patients had been taking latanoprost, or other 
eye drops for IOP, directly prior to this investigation. The vast 
majority of the patients had taken latanoprost in the past, but 
had   discontinued at least one month prior to participation in 
this trial (wash-out period). None of the recruited patients 
had cataract and there were no cases of pseudophakic eyes 
present.
For the safety of the patients taking the supplement 
only, it was planned to give them latanoprost in addition, 
should their IOP not show satisfactory signs of improvement 
  during the two months. After four weeks of treatment with 
Mirtogenol a nonsignificant decrease to 34.1 ± 4.0 mmHg 
was found. After six weeks’ intake of the dietary   supplement 
the IOP decreased significantly compared to baseline, 
to value 33.3 ± 5.0 mmHg (P , 0.05). As there were 
no   nonresponders, none of the patients treated with the 
  supplement only were transferred to the group taking 
  latanoprost in combination treatment.
Latanoprost showed a significantly faster and more 
  pronounced lowering of IOP than in the group taking 
  Mirtogenol (Figure 1). Latanoprost had already   significantly 
lowered IOP after four weeks to 27.2 ± 0.9 mmHg (P , 0.05 
compared to baseline values). At all time points after trial 
start the IOP in the latanoprost group was significantly 
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Figure 1 The development of intraocular pressure (iOP) in the three groups receiving Mirtogenol, latanoprost or both, respectively, over the investigational period of 
24 weeks. Mirtogenol significantly decreased IOP compared to baseline after six weeks and all later time points during the study (P , 0.05). Latanoprost alone, as well as in 
combination with Mirtogenol, lowered iOP after four weeks, and onwards (P , 0.05). Clinical Ophthalmology  2010: 4 submit your manuscript | www.dovepress.com
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its effect on IOP, with significant activity detectable within 
as little as eight hours after a single dose.12 The combined 
treatment with latanoprost and the supplement significantly 
decreased IOP after four weeks, an effect predominantly 
attributed to latanoprost. Interestingly, after six weeks, and 
at all later time points, the IOP was lower in subjects receiv-
ing the combination treatment than in the group taking the 
eye drops exclusively. After 16 weeks, the IOP values were 
significantly lower with the combination treatment than with 
latanoprost alone (P , 0.05).
Comparison of the individual IOP-lowering effects of 
the supplement and latanoprost with the combination treat-
ment suggests additive affects, not synergistic activities. The 
additive effects of the supplement and latanoprost point to 
different pharmacologic activities involved for lowering IOP. 
Latanoprost has been extensively investigated for its pharma-
cologic activities.13 The prostaglandin F2α analogues (PGF2α) 
enhance drainage of aqueous humor, predominantly via the 
lower than in the group taking the dietary supplement 
(P , 0.05).
After six weeks of treatment, the combination of 
latanoprost eye drops together with the dietary supplement 
decreased the IOP values better than latanoprost alone, or the 
supplement alone. The IOP values of patients on   combination 
treatment were significantly lower than those of the two 
groups having individual treatment, at time points 16, 20 
and 24 weeks, respectively (P , 0.05).
At baseline the blood flow velocity of the central retinal 
artery in the latanoprost group was slightly, but nonsignifi-
cantly, higher than in the two other groups. In all groups 
the diastolic and systolic components of the blood flow 
velocities increased gradually with treatment duration as 
detailed in Tables 2 and 3. The supplement and latanoprost 
contribute in a   comparable fashion to improve the central 
retinal artery blood flow. Only after six weeks was the sys-
tolic blood flow velocity in the   Mirtogenol group higher 
than in the   latanoprost group.   However, the combination of 
  Mirtogenol and latanoprost yielded a better blood flow than 
both   medications taken individually. The diastolic blood 
flow with the combination treatment was higher than with 
individual treatments from 16 weeks onwards (P , 0.05).
Both treatments were well-tolerated with minor transient 
side-effects resulting from latanoprost. In the latanoprost 
group, three subjects reported temporary blurred vision, 
and one patient presented with eyelid redness. In the group 
treated with latanoprost eye drops in addition to Mirtogenol, 
two subjects reported blurred vision, and another two suffered 
conjunctival hyperemia. It is impossible to identify which 
treatment regimen accounted for these minor side effects, but 
they are typical for latanoprost.11 In the group   taking Mirtog-
enol alone no side effects occurred. None of the patients in 
this trial discontinued participation before completion.
Discussion
This study has confirmed the IOP-lowering activity of 
  Mirtogenol, finding a significant activity in dosages lower 
than those previously reported.1 A vis-à-vis response evalu-
ation was not possible because of differences in the baseline 
IOP values of patients in the two studies (39 mmHg versus 
25 mmHg as mean values), but the higher Mirtogenol 
dose in the previous study had a faster effect.1 As expected 
latanoprost relieved ocular hypertension much more rapidly 
than the dietary supplement. The activity of latanoprost had 
already reached maximum effect by the time of the four week 
measurement, and thereafter no further decrease of IOP could 
be observed. Latanoprost is well described for the rapidity of 
Table 3 The development of the systolic blood flow velocity in 
response to treatment as established employing high resolution 
color duplex ultrasonography
Week Systolic blood flow velocity of the central retinal 
artery (cm/s)
Mirtogenol Latanoprost Combination
0 18.0 ± 2.0 18.6 ± 3.1 18.0 ± 3.0
4 21.0 ± 1.3 18.8 ± 1.1 19.0 ± 2.9
6 22.3 ± 1.0*,# 19.3 ± 1.8 23.5 ± 1.9*
12 21.5 ± 1.1* 22.4 ± 1.0* 24.6 ± 2.0*
16 21.5 ± 1.0* 22.0 ± 2.0* 24.0 ± 2.1*
20 21.0 ± 1.0* 23.0 ± 1.0* 25.3 ± 0.9*,‡
24 21.0 ± 1.0* 23.0 ± 1.0* 25.0 ± 2.0*,‡
Notes: *statistical significance to baseline values (P , 0.05). ‡statistical significance of 
the combination treatment versus Mirtogenol-only treated group (P , 0.05). #statistical 
significance of the values of Mirtogenol versus latanoprost group (P , 0.05).
Table 2 The development of the diastolic blood flow velocity 
in response to treatment, measured using high resolution color 
duplex ultrasonography
Week Diastolic blood flow velocity of the central retinal 
artery (cm/s)
Mirtogenol Latanoprost Combination
0 2.5 ± 0.4 3.1 ± 1.0 2.4 ± 1.0
4 4.0 ± 1.1 4.5 ± 1.1 6.0 ± 2.1
6 4.3 ± 1.0 4.7 ± 1.0 6.6 ± 1.5
12 4.9 ± 1.1* 5.4 ± 1.0* 6.9 ± 2.1*,‡
16 5.5 ± 1.0* 5.1 ± 2.0* 7.0 ± 2.1*,‡
20 5.2 ± 1.0* 5.3 ± 1.0* 7.2 ± 0.9*,‡
24 6.0 ± 1.0*,§ 5.0 ± 1.0* 7.0 ± 2.0*,‡
Notes: *statistical significance to baseline values (P , 0.05). ‡statistical significance of 
the combination treatment versus both individual treatments (P , 0.05). §statistical 
significance between values of Mirtogenol and latanoprost groups (P , 0.05).Clinical Ophthalmology  2010: 4 submit your manuscript | www.dovepress.com
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uveoscleral outflow pathway, though significant effects on 
the trabecular outflow facility have also been reported. The 
PGF2α are suggested to stimulate remodeling of the extracel-
lular matrix of the ciliary muscle and sclera.
We speculate that the effect of the combination of Mirtose-
lect and Pycnogenol predominantly affects vascular responses 
involved in ocular hypertension by   normalising capillary fil-
tration of the ciliary body. Pharmacologic   studies have dem-
onstrated that Mirtoselect counteracts the   hyperpermeability 
of ciliary capillaries, initiated by   paracentesis, as measured 
by the Evans Blue   concentration in the aqueous humor.7,14 
Pycnogenol was shown to improve endothelial function6 and 
to lower blood pressure in   asymptomatic hypertension.15 The 
improved ocular blood flow shown in this study supports the 
assumption that the dietary supplement may exert an action 
on lowering IOP by decreasing humor inflow. Yet, it will 
remain difficult to identify whether the supplement affects 
outflow pathways, or aqueous humor inflow, or both.
There is growing evidence that decreased endothelial 
function is the primary cause of age-related deterioration 
of ocular hemodynamics leading to glaucoma.5 In this 
study, an improved blood flow velocity of the central retinal 
artery was again shown for the supplement, but also found 
in the latanoprost group. Interestingly, this effect could be 
  demonstrated earlier in the supplement group than in the 
latanoprost group. After six weeks’ treatment, the systolic 
blood flow rate was significantly higher with the supplement 
than with the eye drops. A measurable, yet nonsignificant, 
increase of central retinal blood flow was described for latano-
prost in   normotensive glaucoma patients after one month of 
treatment.16 However, the authors argue that the improved 
ocular hemodynamics may be secondary to the reduction 
of intraocular pressure. This might explain the increased 
blood flow velocity in this study, for patients treated with 
latanoprost. Indeed, the same explanation might underlie 
the improved hemodynamics observed with the supplement, 
and with its combination with latanoprost. Our study has 
a limitation resulting from the use of color Doppler imag-
ing (CDI). As it is impossible to determine the   diameter of 
orbital vessels in vivo, CDI cannot reflect the blood   volume. 
However, other groups have described a correlation between 
blood flow velocity and vascular blood volume.17 Further 
research will be required to draw conclusions about the 
pharmacologic activities of Mirtogenol as a single agent, as 
well as in combination with latanoprost.
A major advantage of the investigated dietary   supplement 
may be the safe, nutritional approach for preventing the 
development of ocular hypertension. This, in turn, would 
decrease the risk of having primary open angle glaucoma 
later in life.18 Latanoprost and related prostaglandin F2α 
represent a valuable tool to treat intraocular hypertension, 
and inhibit its progression to glaucoma, but are unsuitable 
as preventative agents, as latanoprost was shown to decrease 
IOP below physiological levels.19 Furthermore, apart from 
irreversible iris pigmentation and abnormal growth and 
darkening of eyelashes, latanoprost seems to have also less-
common but more-serious side-effects, like the induction 
of iris cysts, cystoid macular edema and anterior uveitis.10 
Conversely, serious side-effects have never been reported for 
Mirtoselect® and Pycnogenol®, despite their decades-old use 
in ophthalmology, predominantly for diabetic retinopathy.2–4 
While the supplement does not represent a replacement for 
prostaglandin F2α analogs, taking the supplement in addition, 
appears to be safe, and may further contribute to the attain-
ment of healthier IOP values.
The results obtained from this, and the previous pilot trial, 
with the dietary supplement Mirtogenol on IOP, appear to 
be very promising. A much larger study with a significant 
number of patients should further assess the benefits of the 
supplement for controlling IOP.
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